HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Making Enzymes, Cosmetics In A Kitchen And Cataloging Disease Claims Attract FDA Warnings

Executive Summary

FDA Office of Regulatory Affairs warned Nature Essence Small Molecule Co. in Lexington, KY, and Warner Herb Co. in Crossville, TN, both single-facility businesses. They likely appeared on FDA radar as it moves from inspecting larger supplement manufacturers for compliance with the 2007 GMP final rule to also reaching small firms.

You may also be interested in...



FDA Supplement GMP Crosshairs More Frequently On Smaller Firms

GMP violation warnings to three small dietary supplement firms in late March reflect a “thoughtful shift” by FDA toward inspections of smaller firms, says UNPA President Loren Israelsen. With the supplement GMP final rule past its 10-year anniversary, firms should be meeting their requirements.

Herbalife Executives' Investments Spark Uptick In Share Price After Results Send Stock Plummeting

Since closing at a 14-year low of $8.07 the day of the execs’ transactions, Herbalife shares trend steadily up from close of $8.26 on 20 February to $8.83 on 29 February. Some execs sell back some shares on 25 February at $8.67.

Infant Formula Production Expansion Brings Problems Souring Perrigo's 2024 Forecast

Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel